Affimed Reports 2023 Financial Results and Operational
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer...
Source: globenewswire.com
Affimednv News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Affimednv . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Affimednv Today - Breaking & Trending Today
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap
Investors have begun to flirt with a sector that has been distinctly out of favor for more than two years.
Source: marketwatch.com
Affimed Announces Acceptance of Abstracts at the 17th
A pre-clinical data set of AFM13 in combination with Artiva Biotherapeutics Inc.’s allogeneic NK cell AB-101 shows that AFM13 enhances the cytotoxic...
Source: globenewswire.com
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohortAFM24 showed...
Source: globenewswire.com
Affimed to Report Full Year 2022 Financial Results &
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving...
Source: globenewswire.com